MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Medtronic plc
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026
$92.77−1.98 (-2.09%)
Close on Oct 19, 2026
- Market cap
- $119.22B
- P/E (TTM)
- 22.8
- Dividend yield
- 3.06%
Medtronic plc revenue by segment
By business segment
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable segment net sales | $33.46B | $33.08B | $31.84B | $31.11B | $30.55B | $30.73B | $30.64B | $30.41B | $29.97B | $29.65B | – | – | 89.1% | +9.5% |
| Cardiovascular | $14.62B | $13.98B | $13.51B | $13.09B | $12.76B | $12.48B | $12.28B | $12.17B | $11.99B | $11.83B | $12.01B | $11.84B | 38.9% | +14.6% |
| Neuroscience | $10.55B | $10.29B | $10.17B | $10.07B | $9.96B | $9.85B | $9.77B | $9.67B | $9.51B | $9.41B | $9.27B | $9.17B | 28.1% | +6.0% |
| Medical Surgical | $9.01B | $8.82B | $8.63B | $8.53B | $8.48B | $8.41B | $8.39B | $8.43B | $8.41B | $8.42B | $8.21B | $8.16B | 24.0% | +6.2% |
| Diabetes | $3.23B | $3.11B | $3.00B | $2.90B | $2.83B | $2.76B | $2.69B | $2.63B | $2.56B | $2.49B | $2.42B | $2.35B | 8.6% | +14.3% |
| Other Operating Segments | – | – | $131.00M | $131.00M | $133.00M | $137.00M | $164.00M | $185.00M | $209.00M | $221.00M | – | – | – | – |
| Operating income | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3.88B | $3.67B | $3.56B | $3.49B | $3.39B | $3.34B | $2.17B | $2.43B | $2.77B | $3.08B | $4.72B | $4.68B | +14.3% |
| Neuroscience | $3.15B | $3.06B | $3.05B | $3.07B | $3.06B | $3.03B | $2.14B | $2.38B | $2.58B | $2.82B | $3.90B | $3.83B | +3.0% |
| Medical Surgical | $2.12B | $2.13B | $2.09B | $2.10B | $2.10B | $2.07B | $1.36B | $1.66B | $1.93B | $2.19B | $3.13B | $3.12B | +1.0% |
| Diabetes | – | – | $519.00M | $512.00M | $492.00M | $491.00M | $197.00M | $265.00M | $333.00M | $394.00M | $403.00M | $392.00M | – |
| Other Segment | – | – | – | – | – | $49.00M | $40.00M | $34.00M | $26.00M | $10.00M | -$11.00M | -$43.00M | – |
By product or service
By region
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total other countries, excluding Ireland | $37.39B | $36.22B | $35.35B | $34.63B | $34.08B | $33.42B | $33.09B | $32.88B | $32.46B | $32.25B | $32.21B | $31.85B | 99.6% | +9.7% |
| United States | $18.78B | $18.10B | $17.78B | $17.52B | $17.31B | $17.17B | $16.97B | $16.85B | $16.72B | $16.56B | $16.70B | $16.64B | 50.0% | +8.5% |
| International | $18.76B | $18.26B | $17.70B | $17.23B | $16.89B | $16.37B | – | – | – | – | – | – | 50.0% | +11.1% |
| Rest of world | $18.61B | $18.12B | $17.57B | $17.11B | $16.77B | $16.25B | $16.12B | $16.03B | $15.74B | $15.69B | $15.51B | $15.21B | 49.6% | +11.0% |
| Ireland | $150.00M | $143.00M | $134.00M | $126.00M | $120.00M | $116.00M | $114.00M | $113.00M | $113.00M | $113.00M | $113.00M | $109.00M | 0.4% | +25.0% |
| Non-U.S. Developed Markets | – | – | – | – | – | – | – | – | – | $9.98B | $9.93B | $9.75B | – | – |
| Emerging Markets | – | – | – | – | – | – | – | – | – | $5.82B | $5.69B | $5.57B | – | – |
| International | – | – | – | – | – | $16.37B | $16.23B | $16.15B | $15.86B | $15.80B | – | – | – | – |
From the segment and revenue-disaggregation notes of Medtronic's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.